Tags

Type your tag names separated by a space and hit enter

Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
J Reprod Med. 2003 May; 48(5):375-80.JR

Abstract

OBJECTIVE

To compare cognitive function in postmenopausal women receiving continuous hormone replacement therapy and those receiving tibolone.

STUDY DESIGN

This was a 6-month, prospective, single-blind, single center, randomized study. A total of 50 healthy, postmenopausal women were enrolled. In the end, 40 women completed the 6-month follow-up. One group (23 subjects) received conjugated equine estrogens (CEE), 0.625 mg/d, and medroxyprogesterone acetate (MPA), 5 mg/d. The other group (17 subjects) received tibolone, 2.5 mg/d. Their serum estradiol levels and Cognitive Abilities Screening Instrument (CASI) and Mini-Mental State Examination (MMSE) scores were obtained before starting and after 3 and 6 months of treatment.

RESULTS

There was a significant increase in the serum estradiol level in the CEE + MPA group, especially after 3 months of treatment, but there was no increase in the estradiol level in the tibolone group. The CASI and MMSE scores of the CEE + MPA group and the tibolone group after 3 and 6 months of treatment showed no significant difference between the two groups apart from the MMSE at the 3-month follow-up. We saw an increasing trend in CASI and MMSE scores after treatment in both groups; however, the increases were not statistically significant. The rate of increase of both CASI and MMSE scores in the CEE + MPA group was greater than in the tibolone group, though the difference was not significant.

CONCLUSION

This preliminary study demonstrated that both CEE + MPA and tibolone can preserve cognitive function and may be able to prevent cognitive decline in postmenopausal women during short-term treatment. Our results also show that continuous, combined CEE + MPA seems to be marginally more effective than tibolone in improving cognitive processes; however, long-term study is needed to follow-up such effect.

Authors+Show Affiliations

Departments of Obstetrics and Gynecology, Public Health and Neurology, National Cheng Kung University Hospital, Tainan, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12815913

Citation

Pan, Hsien-An, et al. "Cognitive Function Variations in Postmenopausal Women Treated With Continuous, Combined HRT or Tibolone. a Comparison." The Journal of Reproductive Medicine, vol. 48, no. 5, 2003, pp. 375-80.
Pan HA, Wang ST, Pai MC, et al. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. J Reprod Med. 2003;48(5):375-80.
Pan, H. A., Wang, S. T., Pai, M. C., Chen, C. H., Wu, M. H., & Huang, K. E. (2003). Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. The Journal of Reproductive Medicine, 48(5), 375-80.
Pan HA, et al. Cognitive Function Variations in Postmenopausal Women Treated With Continuous, Combined HRT or Tibolone. a Comparison. J Reprod Med. 2003;48(5):375-80. PubMed PMID: 12815913.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. AU - Pan,Hsien-An, AU - Wang,Shan-Tair, AU - Pai,Ming-Chyi, AU - Chen,Chih-Hung, AU - Wu,Meng-Hsing, AU - Huang,Ko-En, PY - 2003/6/21/pubmed PY - 2003/9/17/medline PY - 2003/6/21/entrez SP - 375 EP - 80 JF - The Journal of reproductive medicine JO - J Reprod Med VL - 48 IS - 5 N2 - OBJECTIVE: To compare cognitive function in postmenopausal women receiving continuous hormone replacement therapy and those receiving tibolone. STUDY DESIGN: This was a 6-month, prospective, single-blind, single center, randomized study. A total of 50 healthy, postmenopausal women were enrolled. In the end, 40 women completed the 6-month follow-up. One group (23 subjects) received conjugated equine estrogens (CEE), 0.625 mg/d, and medroxyprogesterone acetate (MPA), 5 mg/d. The other group (17 subjects) received tibolone, 2.5 mg/d. Their serum estradiol levels and Cognitive Abilities Screening Instrument (CASI) and Mini-Mental State Examination (MMSE) scores were obtained before starting and after 3 and 6 months of treatment. RESULTS: There was a significant increase in the serum estradiol level in the CEE + MPA group, especially after 3 months of treatment, but there was no increase in the estradiol level in the tibolone group. The CASI and MMSE scores of the CEE + MPA group and the tibolone group after 3 and 6 months of treatment showed no significant difference between the two groups apart from the MMSE at the 3-month follow-up. We saw an increasing trend in CASI and MMSE scores after treatment in both groups; however, the increases were not statistically significant. The rate of increase of both CASI and MMSE scores in the CEE + MPA group was greater than in the tibolone group, though the difference was not significant. CONCLUSION: This preliminary study demonstrated that both CEE + MPA and tibolone can preserve cognitive function and may be able to prevent cognitive decline in postmenopausal women during short-term treatment. Our results also show that continuous, combined CEE + MPA seems to be marginally more effective than tibolone in improving cognitive processes; however, long-term study is needed to follow-up such effect. SN - 0024-7758 UR - https://www.unboundmedicine.com/medline/citation/12815913/Cognitive_function_variations_in_postmenopausal_women_treated_with_continuous_combined_HRT_or_tibolone__A_comparison_ L2 - https://medlineplus.gov/hormonereplacementtherapy.html DB - PRIME DP - Unbound Medicine ER -